"Biosimilar and Biobetter Scenarios for the U.S. and Europe: What Should We Expect?"

Berndt, Ernst R. and Mark R. Trusheim. In Biobetters: Optimizing Protein Therapeutics, edited by Amy Rosenberg and Barthelemy Demeule, 315-360. New York, NY: Springer Science + Business Media, 2015.

"Antipsychotic Prescribing: Do Conflict of Interest Policies make a Difference?"

Huskamp, Haiden, Timothy Anderson, Colleen Barry, Andrew Epstein, Sharon- Lise T. Normand, Aiju Men, Ernst R. Berndt and Marcela Horvitz-Lennon. Medical Care Vol. 53, No. 4 (2015): 338-345.

"The Heterogeneity of Concentrated Prescribing Behavior: Theory and Evidence from Antipsychotics."

Berndt, Ernst R., Robert S. Gibbons, Anton Kolotilin and Anna Levine Taub. Journal of Health Economics Vol. 40, (2015): 26-39.

"Decline in Economic Returns from New Drugs Raises Questions about Sustaining Innovations."

Berndt, Ernst R., Deanna Nass, Michael Kleinrock and Murray Aitken. Health Affairs Vol. 34, No. 2 (2015): 245-252.

"Pricing in the Market for Anticancer Drugs."

Howard, David H., Peter B. Bach, Ernst R. Berndt and Rena M. Conti. Journal of Economic Perspectives Vol. 29, No. 1 (2015): 1- 26.

"Ethics and Economics: New Drug Development."

Ernst Rudolf Berndt and Leonard M. Fleck. In Proceedings of the 2014 DeVos Medical Colloquy, Grand Rapids, MI: September 2014.